Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.62 |
| ▸ | DPP4 | P27487 | 4/20 | 0.59 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8352617 | 0.96 | HTR3A (0.58) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL8349789 | 0.83 | DPP4 (0.56) | DPP4KDM4EALDH1A1TSHRHTT | |
| SCHEMBL13217754 | 0.82 | HTR3A (0.57) | HTR3ADPP4SOS1ALDH1A1HSD17B10 | |
| SCHEMBL13200999 | 0.81 | HTR3A (0.62) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL8353852 | 0.80 | DPP4 (0.63) | DPP4 | |
| SCHEMBL8352589 | 0.80 | HTR3A (0.61) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL13200858 | 0.79 | DPP4 (0.63) | HTR3ADPP4SOS1PIM1 | |
| SCHEMBL8351230 | 0.79 | DPP4 (0.50) | DPP4KDM4EALDH1A1TSHRHTT | |
| SCHEMBL6380045 | 0.78 | DPP4 (0.61) | HTR3ADPP4 | |
| SCHEMBL13200852 | 0.78 | HTR3A (0.61) | HTR3ADPP4SOS1PIM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | disclosed |
| EP-1569936-B1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-03-18 | — | — | EP | disclosed |
| US-7109192-B2 | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2005-01-27 | — | — | US | disclosed |
| WO-2004050658-A1 | NOVEL SUBSTITUTED IMIDAZO-PYRIDINONES AND IMIDAZO-PYRIDAZEIONES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020574-A1 | New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | HTR3A 633/4885DPP4 1/4885SOS1 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.